Evidence Grade A — Regulatory approved. 4194 published studies. 35 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Desmopressin (sold as DDAVP, Stimate, Nocdurna, and other brands) is a modified version of a natural hormone that helps the body concentrate urine and retain water. Available as tablets, nasal spray, and injection, it is used for a wide range of conditions including diabetes insipidus (a condition causing excessive urination), bedwetting in children, night-time urination in adults, and certain bleeding disorders.
Desmopressin is also known by these brand and alternate names:
4,194 published studies: 3239 human, 314 animal, 147 in-vitro, 951 reviews
Desmopressin is marketed under multiple brand names including DDAVP, Stimate, Nocdurna (sublingual), and Noctiva (nasal), with the first approval around 1978. It is one of the most versatile peptide medications available, with indications spanning central diabetes insipidus, primary nocturnal enuresis (bedwetting), nocturia (night-time urination), and mild haemophilia A/von Willebrand disease.
The most important safety concern is hyponatraemia (dangerously low sodium levels) from excessive water retention, particularly in elderly patients. Fluid intake must be restricted around dosing. The sublingual formulation Nocdurna (approved 2018) for nocturia offers improved dosing precision with lower hyponatraemia risk compared to older formulations.
The two modifications to natural vasopressin give desmopressin a very specific profile: it strongly activates the kidney's water-retention receptors (V2) while having minimal effect on the blood vessel-constricting receptors (V1a). This means it concentrates urine powerfully without the dangerous blood pressure effects of vasopressin. The V2 receptor activation also triggers the release of von Willebrand factor and Factor VIII from blood vessel lining cells, which is why desmopressin helps with certain bleeding disorders like mild haemophilia A and von Willebrand disease.
Desmopressin has been a standard treatment for central diabetes insipidus for over 40 years and is also uniquely valuable for mild haemophilia A and von Willebrand disease, where it can boost the body's own clotting factors enough to avoid the need for blood-derived products during minor procedures. Newer formulations have expanded its use: Nocdurna (a sublingual tablet) was approved in 2018 for adults bothered by waking frequently to urinate at night, with sex-specific dosing designed to reduce the main safety risk. That main risk is dangerously low sodium levels (hyponatraemia) caused by excessive water retention, particularly in elderly patients. Fluid restriction around dosing is essential. An earlier intranasal formulation for childhood bedwetting was withdrawn in 2007 after cases of severe hyponatraemia in children. The market is now largely generic, with limited ongoing research.
PeptideTrace tracks 35 registered clinical trials for Desmopressin sourced from ClinicalTrials.gov.
DDAVP Effect by TEG6 in Cardiac Surgery
Transfusion Reduction in High-Bleeding-Risk Cardiac Surgery With Desmopressin
Effectiveness of Pelvic Floor Muscle Rehabilitation Combined With Desmopressin in Children With Primary Monosymptomatic Nocturnal Enuresis
Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIAD
Intravenous Tranexamic Acid and Intramyometrial Desmopressin Effect on Blood Loss During Laparoscopic Myomectomy.
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 2
FDA SUPPL 5
FDA SUPPL 8
FDA SUPPL 9
FDA SUPPL 10
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 13
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 2
FDA SUPPL 4
FDA SUPPL 2
Health Canada Market Authorisation
FDA SUPPL 3
FDA SUPPL 17
FDA SUPPL 5
FDA SUPPL 19
FDA SUPPL 8
FDA SUPPL 10
FDA SUPPL 23
FDA ORIG 1
FDA SUPPL 13
FDA SUPPL 27
FDA SUPPL 13
FDA SUPPL 5
FDA ORIG 1
FDA SUPPL 16
FDA SUPPL 17
FDA SUPPL 8
FDA SUPPL 15
FDA ORIG 1
FDA SUPPL 29
FDA ORIG 1
FDA ORIG 1
FDA SUPPL 35
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 1
FDA SUPPL 22
FDA SUPPL 23
FDA SUPPL 39
FDA ORIG 1
FDA SUPPL 20
FDA SUPPL 8
FDA SUPPL 8
Desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP) is a synthetic analogue of vasopressin with two key modifications: deamination of cysteine at position 1 (extending half-life and reducing V1a pressor activity) and D-arginine at position 8 (conferring selective V2 receptor agonism and further protease resistance). These modifications produce a compound with dramatically enhanced V2 selectivity and virtually no V1a pressor effect.
Desmopressin selectively activates V2 receptors on renal collecting duct principal cells, stimulating cAMP-mediated translocation of aquaporin-2 water channels to the apical membrane, concentrating urine and reducing urine output. Additionally, V2 receptor activation on vascular endothelial cells triggers exocytosis of Weibel-Palade bodies, releasing stored von Willebrand factor (vWF) and Factor VIII into the circulation—the basis for its hemostatic indication.
Desmopressin is marketed as DDAVP, Stimate, Nocdurna, and Noctiva. First approved approximately 1978. Multiple formulations: oral tablets, nasal spray, subcutaneous/IV injection, and sublingual tablets (Nocdurna approved June 21, 2018; Noctiva nasal approved March 3, 2017). Indications include central diabetes insipidus, primary nocturnal enuresis (children ≥6 years), nocturia (adults), and hemophilia A/von Willebrand disease Type 1 (Stimate nasal spray—releases stored Factor VIII and vWF). Carries a boxed warning for hyponatremia/water intoxication.
Linaclotide is marketed as Linzess (approved August 2012). It is taken as a daily oral capsule on an empty stomach, at least 30 minutes before the first meal. The recommended dose is 290 mcg for IBS-C and 72 or 145 mcg for chronic constipation. In clinical trials, approximately 34% of IBS-C patients met the composite improvement endpoint compared to 17% on placebo. Diarrhoea is the most common side effect (approximately 20%) and the leading reason for discontinuation. Linaclotide has a boxed warning against use in children under 6 years due to deaths in young mice, though no such events have been reported in humans. It competes with plecanatide (which targets the same pathway) and other IBS-C treatments.
Elamipretide (Forzinity) was approved by the FDA for Barth syndrome based on the TAZPOWER trial. The randomised crossover phase (12 patients) did not meet its primary endpoints, but the open-label extension (168 weeks) demonstrated durable improvements in walking distance and muscle strength that formed the basis for approval. Barth syndrome affects approximately 1 in 300,000–400,000 births. A larger Phase III trial in primary mitochondrial myopathy (218 patients, MMPOWER-3) did not meet its primary endpoint, and the drug was not approved for that broader indication. Elamipretide remains approved exclusively for Barth syndrome. See also SS-31 (#158) for the research compound context.
Glucagon has been available as an emergency injection since the 1960s and remains the standard rescue treatment for severe hypoglycaemia. Recent innovation has focused on making it easier to administer in emergencies. Baqsimi, approved in 2019, was the first needle-free option as a nasal powder. Gvoke, also approved in 2019, eliminated the need to mix and reconstitute the medication before injection — a significant advance since severe hypoglycaemia often impairs the ability to follow complex preparation steps. Dasiglucagon (Zegalogue), a next-generation stable liquid glucagon approved in 2021, further improved on the convenience of rescue administration. Beyond emergency rescue, glucagon's receptor is now a major research target — dual and triple agonists combining glucagon receptor activity with GLP-1 (such as survodutide and retatrutide) are in advanced clinical trials for obesity and metabolic disease.
Comparisons
Timelines
Regulatory Status
Deep Dives
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
